For laboratory research use only. Not for human or veterinary use.
CJC-1295 WITH DAC

FOR RESEARCH USE ONLYNot for human or veterinary use of any kind
Full label. Lot number and expiry differ per batch and are printed on each vial.
GHRH Analogs & GH SecretagoguesPopular Research Peptides
CJC-1295 with DAC
Also known as: CJC-1295 DAC, DAC:GRF
CJC-1295 with DAC is a synthetic growth hormone-releasing hormone (GHRH) analogue with an albumin-binding drug affinity complex. It is studied for prolonged exposure and effects on GH and IGF-I signaling, and is supplied as a lyophilized powder for laboratory research.
- CAS
- 446262-90-4 (DAC free form)[5]
- M.W.
- Approximately 3.65 kDa (unconjugated free peptide)
- Formula
- C165H269N47O46
- Form
- Lyophilized powder
$49.00per vial
Price shown per vial. Quantity discounts below.
In stock
Buy more, pay less per vial
Add 1 more vial to save 3%: $47.53 per vial.
- Safe credit card paymentVisa, Mastercard and American Express
- 30-day money-back guarantee
- Super-fast 1-2 day shippingTo all 50 states and DC
- Free shipping on orders over $200Applied automatically at checkout

CJC-1295 with DAC
5 mg · $49.00/vial
Lyophilized CJC-1295 with DAC storage
Keep sealed, dry and protected from light. Follow the label, SDS and lot-specific temperature and expiry instructions.
Reconstituted CJC-1295 with DAC storage
Validate solution stability for the experimental conditions.
CJC-1295 with DAC delivery and shipping
CJC-1295 with DAC ships from US stock to United States addresses only. Orders are packed and dispatched within 1-2 business days.
- Standard: $9.95, 1-2 business days after dispatch.
- Express: $24.95, next business day after dispatch.
Lyophilized CJC-1295 with DAC ships in a sealed glass vial with protective packaging. The dry powder is stable at room temperature for the length of domestic transit, so no cold pack is needed. Move it to the storage conditions above when it arrives.
Follow your parcel any time on the Track Order page.
CJC-1295 with DAC lab testing and COA
The certificate of analysis for CJC-1295 with DAC is being uploaded. Ask support for the current report before you order if you need it now.
Every vial label has a lot number. Check it on the Verify page to confirm the vial is genuine. All reports are on the Lab Reports page.
For laboratory research use only. All products are sold for laboratory research use only. They are not drugs, foods, cosmetics or dietary supplements, and are not for human or veterinary use.
CJC-1295 with DAC specifications
- Product
- CJC-1295 with DAC
- Also known as
- CJC-1295 DAC, DAC:GRF
- Compound class
- GHRH Analogs & GH Secretagogues
- Product type
- Peptide
- Form
- Lyophilized powder
- Amounts available
- 5 mg ($49.00), 10 mg ($89.00)
- Chemical class
- GHRH analogue; growth hormone secretagogue
- Peptide structure
- Modified 29-residue core plus DAC-bearing Lys (30 residues)
- Key modification
- C-terminal maleimidopropionyl-Lys; albumin-reactive group
- Molecular formula
- C165H269N47O46
- Molecular weight
- Approximately 3.65 kDa (unconjugated free peptide)
- CAS number
- 446262-90-4 (DAC free form)[5]
- Research focus
- Albumin conjugation; GH-axis pharmacology; biomarkers
- Storage as supplied
- Sealed, dry, dark; -20 °C for long-term storage
- Lab report
- COA on request
- Research areas
- GHRH Analogs & GH Secretagogues, Popular Research Peptides
- Intended use
- Laboratory research only. Not for human or veterinary use.
Research overview
About CJC-1295 with DAC
Scientifically reviewed by John Johnson · Updated November 2026CJC-1295 with DAC is a synthetic growth hormone-releasing hormone (GHRH) analogue with an albumin-binding drug affinity complex. It is studied for prolonged exposure and effects on GH and IGF-I signaling, and is supplied as a lyophilized powder for laboratory research.[5]
DAC stands for drug affinity complex. The distinguishing feature is a reactive maleimide-containing group designed to form a covalent bond with serum albumin. This changes the circulating profile of the peptide and underlies the long-acting CJC-1295 described in the foundational literature.[5]
The DAC form and the 29-residue peptide commonly sold as CJC-1295 without DAC are distinct research materials. A catalog name alone cannot establish which structure is present; the lot-specific identity data should resolve the form.[5]
What Is CJC-1295 with DAC?
The peptide contains a modified GHRH(1-29) core with substitutions at positions 2, 8, 15 and 27, plus a C-terminal lysine carrying the albumin-reactive group. The added group enables conjugation to a free thiol on albumin, while the peptide component retains GHRH-related biological activity.[5]
This makes exposure duration a central research question. It also makes the exact chemical form important: unconjugated peptide, albumin-bound material and degradation products are analytically different species.
CJC-1295 with DAC Research Applications
CJC-1295 with DAC is documented in the following areas of experimental endocrine and analytical research:
- Albumin bioconjugation: Investigating how a maleimide-bearing peptide forms an albumin conjugate and retains activity. The original study examined conjugates in vitro and GH responses in rat pituitary-cell and animal experiments.[1]
- GH and IGF-I pharmacodynamics: Studying sustained endocrine responses in healthy adults. Teichman and colleagues reported increased mean GH and IGF-I after exposure to the long-acting DAC analogue.[2]
- Exposure duration: Characterizing the long circulating profile of the studied material. The estimated human half-life in the 2006 trial was 5.8-8.1 days; that value describes the DAC compound under those study conditions.[2]
- GH secretion patterns: Examining whether prolonged GHRH stimulation changes the pattern of GH release. Ionescu and Frohman reported preserved pulsatility with elevated trough and mean GH, showing that sustained exposure and pulsatile secretion can coexist.[3]
- Exploratory biomarker research: Investigating serum-protein changes associated with GH/IGF-I-axis activation. A study of samples from 11 healthy men used proteomics to explore candidate biomarkers; the findings require further validation.[4]
Evidence in context. The human papers primarily characterize pharmacokinetics, endocrine responses and exploratory biomarkers. They do not establish a benefit for muscle growth, recovery, fat loss or longevity. FDA has separately highlighted limited clinical data and safety concerns associated with CJC-1295.[5][6]c
Catalog and source notes
| Catalog amounts / price | 5 mg: $49.00 | 10 mg: $89.00a |
| Shipping | US addresses only; listed dispatch time 1-2 business days. Standard shipping from $9.95.a |
| Lab reports / identity | COA on request. Use the vial lot number to request the matching analytical report and SDS. |
| Storage / handling | Keep sealed, dry and protected from light. Follow the label, SDS and lot-specific temperature and expiry instructions. Validate solution stability for the experimental conditions. |
Catalog source: local CJC-1295 with DAC product page. Prices, availability and shipping terms may change. Confirm the current listing before ordering.
a. Vial sizes and commercial details reflect the local catalog on 12 November 2026; confirm the current listing and matching lot COA. b. Formula and mass describe the free peptide; counterions, water and other lot constituents are excluded. Confirm the supplied chemical form.
c. Pharmacokinetics describes compound exposure; pharmacodynamics describes measured biological responses. Neither is a clinical benefit claim.
Laboratory research only. The published multi-day exposure profile applies to the DAC-bearing compound, not the non-DAC product.
Sources and catalog checked 12 November 2026. Descriptive reference titles are labeled; article links identify the full publications.
Numbered citations throughout this description link directly to the sources below. Model notes identify the evidence each source provides.
CJC-1295 with DAC FAQ
What does DAC mean?
DAC means drug affinity complex. In CJC-1295 with DAC, a maleimide-containing group on the added lysine provides the chemistry for covalent albumin binding. It is a structural modification, rather than a separate ingredient mixed into the vial.[5]
Is this the same as CJC-1295 without DAC?
No. The DAC compound includes an additional albumin-reactive unit. The non-DAC material is commonly called modified GRF(1-29). Their molecular identities and exposure profiles differ, so the two forms should be distinguished in both specifications and research interpretation.[5]
How many amino acids are in CJC-1295 with DAC?
The structure comprises a modified 29-residue GHRH core and an added C-terminal lysine, giving 30 amino-acid residues. The maleimidopropionyl group is attached to that lysine; it is not an additional amino acid.[5]
Does the DAC form eliminate GH pulses?
No. A human physiology study observed preserved GH pulsatility during prolonged stimulation by the albumin-binding analogue, alongside an increase in trough and mean GH. Long peptide exposure does not mean a completely flat GH secretion pattern.[3]
Can the human half-life estimate be applied to the non-DAC product?
No. The 5.8-8.1-day estimate comes from the long-acting DAC study. It should not be quoted as the half-life of modified GRF(1-29) or used to infer the stability of a research vial on the shelf.[5]
Is CJC-1295 with DAC an approved medicine?
CJC-1295 with DAC is not an FDA-approved medicine. FDA has noted limited clinical data, potential immunogenicity and peptide-impurity concerns, and reports of increased heart rate and systemic vasodilatory reactions associated with CJC-1295.[6]
What analytical details matter for the DAC form?
Check that the certificate identifies the DAC structure, the salt or counterion, the identity method and the lot number. Chromatographic purity alone does not establish albumin-binding activity or resolve ambiguous naming. The current catalog lists the COA as available on request.[5]a
Scientific references
- [1]Jette L, et al. (2005). Albumin-linked hGRF(1-29) analogues and the identification of long-acting CJC-1295 [descriptive title]. Endocrinology. 146(7):3052-3058. doi: 10.1210/en.2004-1286. DAC chemistry; rat cells and animal experiments.
- [2]Teichman SL, et al. (2006). Prolonged GH and IGF-I stimulation with long-acting CJC-1295 in healthy adults [descriptive title]. J Clin Endocrinol Metab. 91(3):799-805. doi: 10.1210/jc.2005-1536. Human pharmacokinetics and pharmacodynamics; DAC form.
- [3]Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 91(12):4792-4797. doi: 10.1210/jc.2006-1702. Human GH secretion-pattern study; DAC form.
- [4]Sackmann-Sala L, et al. (2009). GH/IGF-I-axis activation by CJC-1295 and changes in serum protein profiles [descriptive title]. Growth Horm IGF Res. 19(6):471-477. doi: 10.1016/j.ghir.2009.03.001. Exploratory human proteomics; long-acting analogue.
- [5]U.S. Food and Drug Administration (2024). CJC-1295-related bulk substances: scientific evaluation in the December 4 PCAC briefing document [descriptive title]. Chemistry and form-specific evidence assessment. Open official source. Distinguishes DAC/non-DAC structures and salt forms.
- [6]U.S. Food and Drug Administration. Certain bulk drug substances for compounding that may present significant safety risks [descriptive title]. CJC-1295 entry; accessed 12 November 2026. Open official source. Official safety context.
Buying CJC-1295 with DAC for research in the USA
Price
From $49.00. 5 mg: $49.00, 10 mg: $89.00. Quantity discounts per size: 3% off 2 vials, 5% off 3-4 vials, 7% off 5+ vials.
Shipping
US addresses only. Orders are packed and dispatched within 1-2 business days. Standard from $9.95.
Proof it's genuine
Check the lot number on your vial on the Verify page.
Lab reports
COA and SDS documents are on the Lab Reports page.
Scientifically reviewed
Scientifically reviewed by John Johnson
Scientific reviewer · Last reviewed November 2026
John Johnson reviewed this CJC-1295 with DAC page for scientific accuracy: the compound's identity and specifications, the summaries of published studies, and the references they cite. The page describes laboratory and preclinical research only. It is not medical advice and gives no usage guidance.
Research information on this page summarizes published laboratory and preclinical studies. It is not usage guidance.




